Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)

BACKGROUND: Neoadjuvant chemotherapy (CT) followed by radiotherapy (RT) and surgery showed a median survival of 28.7 months in resectable stage IIIB non-small-cell lung cancer (NSCLC) patients (pts). Here, we evaluate the impact of concomitant cetuximab to the same neoadjuvant chemo-radiotherapy (CR...

Descripción completa

Detalles Bibliográficos
Autores principales: Curioni-Fontecedro, Alessandra, Perentes, Jean Yannis, Gelpke, Hans, Xyrafas, Alexandros, Bouchaab, Hasna, Mach, Nicolas, Matzinger, Oscar, Stojcheva, Nina, Frueh, Martin, Weder, Walter, Cathomas, Richard, Gargiulo, Piera, Bubendorf, Lukas, Pless, Miklos, Betticher, Daniel, Peters, Solange
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734655/
https://www.ncbi.nlm.nih.gov/pubmed/30988393
http://dx.doi.org/10.1038/s41416-019-0447-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734655/
https://www.ncbi.nlm.nih.gov/pubmed/30988393
http://dx.doi.org/10.1038/s41416-019-0447-0

Ejemplares similares